Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mouad Abouqateb

Showing results (1-10 of 10) with videos related to

Pageof 1
Sort By:
Kidney International|January 20, 2024
The authors replyNicolas Benichou, Mouad Abouqateb, Alexandre Karras, et al.
American Journal of Preventive Cardiology|January 14, 2025
Vascular ageing manifestations and hypertension in the communityGuillermo A Alanis, Pierre Boutouyrie, Mouad Abouqateb, et al.
Leukemia|June 25, 2024
How risky is a second allogeneic stem cell transplantation?Olaf Penack, Mouad Abouqateb, Christophe Peczynski, et al.
Blood Cancer Journal|March 15, 2024
PTCy versus ATG as graft-versus-host disease prophylaxis in mismatched unrelated stem cell transplantationOlaf Penack, Mouad Abouqateb, Christophe Peczynski, et al.
Leukemia|March 28, 2024
ATG or post-transplant cyclophosphamide to prevent GVHD in matched unrelated stem cell transplantation?Olaf Penack, Mouad Abouqateb, Christophe Peczynski, et al.
Leukemia|April 17, 2025
GVHD prophylaxis in matched related stem cell transplantation: Why post-transplant cyclophosphamide can be recommended a study by the EBMT transplant complications working partyOlaf Penack, Mouad Abouqateb, Christophe Peczynski, et al.
Bone Marrow Transplantation|August 19, 2025
Post-transplantation cyclophosphamide and antithymocyte globulin in 8/10 HLA-mismatched unrelated donor transplantation: the analysis on behalf of the transplant complications working party of the EBMTIvan Moiseev, Mouad Abouqateb, Christophe Peczynski, et al.
British Journal of Haematology|September 30, 2025
Outcomes after a second allogeneic haematopoietic stem cell transplant for relapsed paediatric acute myeloid leukaemia improved over time: A study from the EBMT Paediatric Diseases Working PartyNimrod Buchbinder, Victor Michel, Arnaud Dalissier, et al.
Bone Marrow Transplantation|September 30, 2025
Single unrelated umbilical cord blood versus unmanipulated haploidentical HCT using PTCy in pediatric AML: a retrospective study on behalf of the EBMT PDWP and CTIWPBenedetta Elena Di Majo, Mouad Abouqateb, Jacques-Emmanuel Galimard, et al.
Bone Marrow Transplantation|September 10, 2025
Improved GVHD-free relapse-free survival when rATG/ATLG is used in allo-HCT from matched sibling donors - an EBMT registry study by the Transplant Complications Working PartyAgnieszka Piekarska, Mouad Abouqateb, William Boreland, et al.
Pageof 1

Showing results (1-10 of 10) with videos related to

Sort By:
Pageof 1
Kidney International|January 20, 2024
The authors replyNicolas Benichou, Mouad Abouqateb, Alexandre Karras, et al.
American Journal of Preventive Cardiology|January 14, 2025
Vascular ageing manifestations and hypertension in the communityGuillermo A Alanis, Pierre Boutouyrie, Mouad Abouqateb, et al.
Leukemia|June 25, 2024
How risky is a second allogeneic stem cell transplantation?Olaf Penack, Mouad Abouqateb, Christophe Peczynski, et al.
Blood Cancer Journal|March 15, 2024
PTCy versus ATG as graft-versus-host disease prophylaxis in mismatched unrelated stem cell transplantationOlaf Penack, Mouad Abouqateb, Christophe Peczynski, et al.
Leukemia|March 28, 2024
ATG or post-transplant cyclophosphamide to prevent GVHD in matched unrelated stem cell transplantation?Olaf Penack, Mouad Abouqateb, Christophe Peczynski, et al.
Leukemia|April 17, 2025
GVHD prophylaxis in matched related stem cell transplantation: Why post-transplant cyclophosphamide can be recommended a study by the EBMT transplant complications working partyOlaf Penack, Mouad Abouqateb, Christophe Peczynski, et al.
Bone Marrow Transplantation|August 19, 2025
Post-transplantation cyclophosphamide and antithymocyte globulin in 8/10 HLA-mismatched unrelated donor transplantation: the analysis on behalf of the transplant complications working party of the EBMTIvan Moiseev, Mouad Abouqateb, Christophe Peczynski, et al.
British Journal of Haematology|September 30, 2025
Outcomes after a second allogeneic haematopoietic stem cell transplant for relapsed paediatric acute myeloid leukaemia improved over time: A study from the EBMT Paediatric Diseases Working PartyNimrod Buchbinder, Victor Michel, Arnaud Dalissier, et al.
Bone Marrow Transplantation|September 30, 2025
Single unrelated umbilical cord blood versus unmanipulated haploidentical HCT using PTCy in pediatric AML: a retrospective study on behalf of the EBMT PDWP and CTIWPBenedetta Elena Di Majo, Mouad Abouqateb, Jacques-Emmanuel Galimard, et al.
Bone Marrow Transplantation|September 10, 2025
Improved GVHD-free relapse-free survival when rATG/ATLG is used in allo-HCT from matched sibling donors - an EBMT registry study by the Transplant Complications Working PartyAgnieszka Piekarska, Mouad Abouqateb, William Boreland, et al.
Pageof 1